The 2026 Compounded GLP-1 Crackdown: What the FDA Did and What It Means for You

The compounded GLP-1 market that grew to roughly a third of US supply at its peak is being dismantled by regulation. If you take or are considering compounded semaglutide or tirzepatide, here is exactly what the FDA did, why, and what it means for your access and cost.

The legal mechanism in one paragraph

Federal law lets pharmacies compound copies of an FDA-approved drug only while that drug is on the FDA’s shortage list. Semaglutide and tirzepatide were added in 2022 during a demand surge. When the FDA confirmed manufacturers could meet demand and removed them from the list, the legal basis for routine compounding disappeared. Everything that followed flows from that.

The timeline

October–December 2024: FDA determines the tirzepatide shortage resolved.
February 21, 2025: FDA declares the semaglutide shortage resolved.
Spring 2025: Enforcement discretion ends — 503A pharmacies (tirzepatide by Feb 19, semaglutide by April 22) and 503B facilities (tirzepatide by March 19, semaglutide by May 22) must wind down.
2025: Courts deny the Outsourcing Facilities Association’s injunction attempts; the deadlines hold. The FDA issues dozens of warning letters; Hims, Ro, and other large telehealth platforms exit compounded semaglutide.
April 30, 2026: FDA proposes excluding semaglutide, tirzepatide, and liraglutide from the 503B bulks list, citing no clinical need for bulk compounding. Public comment runs through June 29, 2026.

Why the FDA did it

Two reasons. First, the legal one above — no shortage means no routine compounding. Second, patient safety: as of early 2025 the FDA had logged more than 455 adverse-event reports for compounded semaglutide and more than 320 for compounded tirzepatide, including dosing errors and hospitalizations, plus sterility and potency failures found in inspections and a flood of online counterfeits. The agency has been explicit that affordability and insurance access do not, by themselves, constitute the “clinical need” that would justify bulk compounding.

What’s still legal

Narrow patient-specific 503A compounding remains, where a prescriber documents a clinical need for a change from the FDA-approved product (for example, an alternative formulation). This is a real but limited lane — not a path for mass-produced standard-dose copies. Our legal status explainer goes deeper.

What it means for cost

As compounded access tightens, the manufacturers filled part of the gap with cash-pay programs: LillyDirect (Zepbound vials ~$349–$499) and NovoCare (semaglutide from ~$149–$499). These are FDA-approved and far below the $1,000+ retail list, narrowing the historical compounded-vs-brand gap. See compounded vs. brand.

What patients should do

Don’t panic or stop abruptly. If you’re on compounded product, talk to your prescriber about your plan.
Verify your provider is in the compliant lane using our checklist.
Know your alternatives — insurance, LillyDirect/NovoCare, or a compliant compounded provider. See switching to brand.
Avoid the cheapest anonymous offers — that’s where counterfeits and “research use only” sellers concentrate.

Bottom line

The 2025–2026 crackdown ended the era of broad, low-cost compounded GLP-1s. A narrow compliant lane remains, the manufacturers cut cash-pay prices, and the safest move for patients is to verify legitimacy and plan with a clinician rather than chase the lowest anonymous price.

Educational, not medical or legal advice. Regulatory status is changing rapidly; confirm current rules with a licensed clinician and your state board of pharmacy.